Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 2, 2016, Pages 387-396

  Cui, X Y ^a,b,c,d   Tinholt, M ^a,c,d   Stavik, B ^a,c   Dahm, A E A ^b,d,e   Kanse, S ^a,c,d   Jin, Y ^d   Seidl, S ^a,c,d   Sahlberg, K K ^d,f,g   Iversen, N ^a   Skretting, G ^a,c   Sandset, P M ^a,c,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^f VESTRE VIKEN HOSPITAL TRUST   (Norway)

^g Oslo Breast Cancer Research Consortium (OSBREAC)   (Norway)

Author keywords

Blood coagulation; Breast cancer; HIF 1 protein; Human; Hypoxia; Tissue factor pathway inhibitor

Indexed keywords

COBALT CHLORIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; TISSUE FACTOR PATHWAY INHIBITOR; HIF1A PROTEIN, HUMAN; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; OXYGEN;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER TISSUE; CHROMATIN IMMUNOPRECIPITATION; DOWN REGULATION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MUTAGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TFPI GENE; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT; UPREGULATION; ADULT; AGED; BINDING SITE; BLOOD CLOTTING; BREAST TUMOR; CELL HYPOXIA; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; MCF-7 CELL LINE; METABOLISM; MIDDLE AGED; PATHOLOGY; TIME FACTOR;

ADULT; AGED; BINDING SITES; BLOOD COAGULATION; BREAST NEOPLASMS; CELL HYPOXIA; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIPOPROTEINS; MCF-7 CELLS; MIDDLE AGED; OXYGEN; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR MICROENVIRONMENT;

EID: 84958257697     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13206     Document Type: Article

References (42)

1. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-50.
2. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122: 1712-23.
3. Prandoni P, Lensing AW, Buller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten Cate JW. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-33.
4. Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D, Dubois C. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 2009; 206: 1913-27.
5. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009; 27: 4834-8.
6. Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood 2014; 123: 2934-43.
7. Tinholt M, Stavik B, Louch W, Carlson CR, Sletten M, Ruf W, Skretting G, Sandset PM, Iversen N. Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells. PLoS One 2015; 10: e0117404.
8. Stavik B, Tinholt M, Sletten M, Skretting G, Sandset PM, Iversen N. TFPIalpha and TFPIbeta are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity. J Hematol Oncol 2013; 6: 5.
9. Abu Saadeh F, Norris L, O'Toole S, Mohamed BM, Langhe R, O'Leary J, Gleeson N. Tumour expression of tissue factor and tissue factor pathway inhibitor in ovarian cancer - relationship with venous thrombosis risk. Thromb Res 2013; 132: 627-34.
10. Sierko E, Wojtukiewicz MZ, Zimnoch L, Kisiel W. Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue. Thromb Haemost 2010; 103: 198-204.
11. Nwabo Kamdje AH, Muller JM, Lukong KE. Signaling pathways in breast cancer: therapeutic targeting of the microenvironment. Cell Signal 2014; 26: 2843-56.
12. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29: 625-34.
13. 2 histography. Antioxid Redox Signal 2007; 9: 1221-35.
14. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
15. 2-regulated gene expression. FASEB J 2002; 16: 1151-62.
16. Semenza GL. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001; 107: 1-3.
17. Rong Y, Post DE, Pieper RO, Durden DL, van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005; 65: 1406-13.
18. Eisenreich A, Zakrzewicz A, Huber K, Thierbach H, Pepke W, Goldin-Lang P, Schultheiss HP, Pries A, Rauch U. Regulation of pro-angiogenic tissue factor expression in hypoxia-induced human lung cancer cells. Oncol Rep 2013; 30: 462-70.
19. Cui XY, Skretting G, Jing Y, Sun H, Sandset PM, Sun L. Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells. Blood Cells Mol Dis 2013; 51: 177-84.
20. 2, a chemical inducer of hypoxia-inducible factor-1, and hypoxia reduce apoptotic cell death in hepatoma cell line HepG2. Ann N Y Acad Sci 2002; 973: 443-7.
21. Skretting G, Stavik B, Landvik NE, Myklebust CF, Iversen N, Zienolddiny S, Sandset PM. Functional characterization of polymorphisms in the human TFPI gene. Biochem Biophys Res Commun 2010; 397: 106-11.
22. Tinholt M, Vollan HK, Sahlberg KK, Jernstrom S, Kaveh F, Lingjaerde OC, Karesen R, Sauer T, Kristensen V, Borresen-Dale AL, Sandset PM, Iversen N. Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF. Breast Cancer Res 2015; 17: 44.
23. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, Ferrara N, Johnson RS. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004; 6: 485-95.
24. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5.
25. Matys V, Fricke E, Geffers R, Gossling E, Haubrock M, Hehl R, Hornischer K, Karas D, Kel AE, Kel-Margoulis OV, Kloos DU, Land S, Lewicki-Potapov B, Michael H, Munch R, Reuter I, Rotert S, Saxel H, Scheer M, Thiele S, et al. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res 2003; 31: 374-8.
26. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959-72.
27. Morote-Garcia JC, Rosenberger P, Nivillac NM, Coe IR, Eltzschig HK. Hypoxia-inducible factor-dependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia. Gastroenterology 2009; 136: 607-18.
28. Zheng W, Kuhlicke J, Jackel K, Eltzschig HK, Singh A, Sjoblom M, Riederer B, Weinhold C, Seidler U, Colgan SP, Karhausen J. Hypoxia inducible factor-1 (HIF-1)-mediated repression of cystic fibrosis transmembrane conductance regulator (CFTR) in the intestinal epithelium. FASEB J 2009; 23: 204-13.
29. Hindryckx P, De Vos M, Jacques P, Ferdinande L, Peeters H, Olievier K, Bogaert S, Brinkman B, Vandenabeele P, Elewaut D, Laukens D. Hydroxylase inhibition abrogates TNF-alpha-induced intestinal epithelial damage by hypoxia-inducible factor-1-dependent repression of FADD. J Immunol 2010; 185: 6306-16.
30. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8: 705-13.
31. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004; 5: 343-54.
32. Galban S, Gorospe M. Factors interacting with HIF-1alpha mRNA: novel therapeutic targets. Curr Pharm Des 2009; 15: 3853-60.
33. Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, Meijer GA, van de Wiel MA, Belien JA, van Diest PJ, van der Wall E. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 2005; 206: 291-304.
34. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012; 12: 9-22.
35. Carrier M, Khorana AA, Zwicker JI, Lyman GH, Le Gal G, Lee AY; subcommittee on Haemostasis and Malignancy for the SSC of the ISTH. Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis. J Thromb Haemost 2012; 10: 2599-601.
36. Hembrough TA, Ruiz JF, Swerdlow BM, Swartz GM, Hammers HJ, Zhang L, Plum SM, Williams MS, Strickland DK, Pribluda VS. Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. Blood 2004; 103: 3374-80.
37. Stavik B, Skretting G, Aasheim HC, Tinholt M, Zernichow L, Sletten M, Sandset PM, Iversen N. Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility. BMC Cancer 2011; 11: 357.
38. Favaro E, Lord S, Harris AL, Buffa FM. Gene expression and hypoxia in breast cancer. Gen Med 2011; 3: 55.
39. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441: 437-43.
40. Wang T, Gilkes DM, Takano N, Xiang L, Luo W, Bishop CJ, Chaturvedi P, Green JJ, Semenza GL. Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. Proc Natl Acad Sci USA 2014; 111: E3234-42.
41. Davies GF, Berg A, Postnikoff SD, Wilson HL, Arnason TG, Kusalik A, Harkness TA. TFPI1 mediates resistance to doxorubicin in breast cancer cells by inducing a hypoxic-like response. PLoS One 2014; 9: e84611.
42. Ueda J, Ho JC, Lee KL, Kitajima S, Yang H, Sun W, Fukuhara N, Zaiden N, Chan SL, Tachibana M, Shinkai Y, Kato H, Poellinger L. The hypoxia-inducible epigenetic regulators Jmjd1a and G9a provide a mechanistic link between angiogenesis and tumor growth. Mol Cell Biol 2014; 34: 3702-20.